Fatty Liver/Adipose Tissue Dual‐Targeting Nanoparticles with Heme Oxygenase‐1 Inducer for Amelioration of Obesity, Obesity‐Induced Type 2 Diabetes, and Steatohepatitis

Persistent uptake of high‐calorie diets induces the storage of excessive lipid in visceral adipose tissue. Lipids secreted from obese adipose tissue are accumulated in peripheral tissues such as the liver, pancreas, and muscle, and impair insulin sensitivity causing type 2 diabetes mellitus (T2DM). Furthermore, the accumulation of inflammatory cytokines and lipids in the liver induces apoptosis and fibrogenesis, and ultimately causes nonalcoholic steatohepatitis (NASH). To modulate obese tissue environments, it is challenged to selectively deliver inducers of heme oxygenase‐1 (HO‐1) to adipose tissue with the aid of a prohibitin targeting drug delivery system. Prohibitin binding peptide (PBP), an oligopeptide targeting prohibitin rich in adipose tissue, is conjugated on the surface of Hemin‐ or CoPP‐loaded poly(lactide‐co‐glycolide) nanoparticles (PBP‐NPs). PBP‐NPs efficiently differentiate lipid storing white adipocytes into energy‐generating brown adipocytes in T2DM and NASH models. In addition, PBP‐NPs are found to target prohibitin overexpressed fatty liver in the NASH model and inhibit hepatic uptake of circulating lipids. Furthermore, PBP‐NPs switch phenotypes of inflammatory macrophages in damaged organs and lower inflammation. Taken together, dual‐targeted induction of HO‐1 in fatty adipose and liver tissues is proven to be a promising therapeutic strategy to ameliorate obesity, insulin resistance, and steatohepatitis by lowering lipids and cytokines.